英语翻译Abstract:The supply problem with regard to drug development and sustainable production lies in the limited amounts of biomass of most marine invertebrates available from wild stocks.Thus,most pharmacologically active marine natural produc

英语翻译Abstract:The supply problem with regard to drug development and sustainable production lies in the limited amounts of biomass of most marine invertebrates available from wild stocks.Thus,most pharmacologically active marine natural produc
英语翻译
Abstract:The supply problem with regard to drug development and sustainable production
lies in the limited amounts of biomass of most marine invertebrates available from wild
stocks.Thus,most pharmacologically active marine natural products can only be isolated in
minute yields.Total synthesis of pharmacologically active natural products has been
successfully established but is in many cases economically not feasible due to the complexity
of the molecular structures and the low yields.To solve the pressing supply issue in marine
drug discovery,other strategies appear to be more promising.One of these is mariculture
which has successfully been established with the bryozoan Bugula neritina (the source of the
bryostatins) and the tunicate Ecteinascidia turbinata (the source of ET-743).Another strategy
involves partial synthesis from precursors which are biotechnologically available.An example
is ET-743 that can be partially synthesized from safracin B which is a metabolite of
Pseudomonas fluorescens.There have been many examples of striking structural similarities
between natural products obtained from marine invertebrates and those of microbial origin
which suggests that microorganisms living in their invertebrate hosts could be the actual
producers of these secondary metabolites.With regard to sustainable biotechnological
production of pharmacologically important metabolites from marine invertebrates and their “endosymbionts”,a more advanced strategy is to focus on cloning and expression of the
respective key biosynthetic gene clusters.This molecular biological approach will open up
new avenues for biotechnological production of drugs or drug candidates from the sea.

英语翻译Abstract:The supply problem with regard to drug development and sustainable production lies in the limited amounts of biomass of most marine invertebrates available from wild stocks.Thus,most pharmacologically active marine natural produc
摘要：关于药物发展和能承受的生产的供应问题 在限制数量的lies多数海洋无脊椎生物量可得到从狂放
stocks.因此,最药物学地活跃海洋自然产品可能只被隔绝
minute出产量.药物学地活跃自然产品总综合是 建立的successfully,但是不经济上在许多情况下可行归结于复杂
of分子结构和低出产量.要解决紧迫的供应发布在海军陆战队员
drug发现,其他战略看来是更加有为的.这些中的一个是海产养殖
which顺利地建立了与苔藓动物Bugula neritina (来源的
bryostatins)和被膜Ecteinascidia turbinata (ET-743的来源).另一个战略 从是生物技术学可利用的前体的involves部份综合.一个例子 可以从safracin B部分地被综合是代谢产物的is ET-743
Pseudomonas Fluorescens.有触击结构相似性的许多例子 从海洋无脊椎和那些获得的between自然产品微生物起源
which建议居住在他们的无脊椎主人的微生物可能是实际的 这些次要代谢产物producers.关于能承受生物技术学 药物学地从海洋无脊椎和他们的“endosymbionts”的重要代谢产物的production,一个更加先进的战略是集中于克隆和表示
respective关键生物合成的基因群.这种分子生物方法将开放 药物或从海的药物候选人的生物技术学的生产的new大道.